Wednesday, August 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 20, 2026

Is This the Right Time to Rebalance Your Portfolio?

View original at nasdaq.com
Is This the Right Time to Rebalance Your Portfolio? Key Points Some investors think it’s prudent to prune their top stocks in a bull market…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Amazon accounts for over 10% of his portfolio

    60% confidence
  • Believes in letting the winners ride instead of selling them too early for the sake of diversification

    60% confidence
  • There is a little-known company called an 'Indispensable Monopoly' providing critical technology both Nvidia and Intel need

    60% confidence
  • Does not plan to prune top stocks anytime soon

    60% confidence
  • Has been invested in stocks for nearly two decades and has never regularly rebalanced portfolio

    60% confidence
  • AI could create the world's first trillionaire

    60% confidence
  • Everybody in the world is a long-term investor until the market goes down

    60% confidence
  • Stock Advisor analyst team identified 10 best stocks for investors to buy now, and Nvidia was not one of them

    60% confidence

Data points we hold from this source

S&P 500 · total return199 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com
Is This the Right Time to Rebalance Your Portfolio? — Source | Via News | ViaNews Market